Please enable Javascript
Advanced Urothelial Carcinoma
Advertisement
NECTIN4 Amplifications as Genomic Predictors of EV Responses in Patients With mUC
Katy Marshall
Advanced Urothelial Carcinoma
|
April 29, 2024
In those who did not undergo EV treatment, NECTIN4 amplifications were not connected with outcomes.
Read More
CheckMate 274: OS Outcomes for Patients With MIBC
Matthew Galsky, MD
Muscle Invasive Urothelial Carcinoma
|
April 25, 2024
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
View More
Molecular Testing and Treatment Sequencing for Advanced UC: Navigating FGFR-Targeted Therapy
Monika Joshi, MD, MRCP
Advanced Urothelial Carcinoma
|
April 17, 2024
Dr. Joshi contextualizes the THOR study within the treatment landscape for FGFR2/3-altered advanced urothelial carcinoma.
View More
Managing mUC With Pembrolizumab, Radical Resection of Primary Tumor
Emily Menendez
Advanced Urothelial Carcinoma
|
April 12, 2024
A case study studied the results of 4 patients with locally advanced or oligometastatic UC with complete response on imaging.
Read More
ICI Use Points to Attrition of Novel Second-line Treatment for mUC
Emily Menendez
Advanced Urothelial Carcinoma
|
March 14, 2024
While ICIs have become a novel treatment option for mUC, attrition rates may affect their impact on long-term survival.
Read More
Dr. Guru Sonpavde on Nivolumab, Gem-Cis FDA Approval and Role in Treating Metastatic Bladder Cancer
Guru P. Sonpavde, MD
Advanced Urothelial Carcinoma
|
March 12, 2024
Dr. Sonpavde provides an overview of the potential of nivo/gem-cis for patients with mUC who are ineligible for EV/pembro.
View More
FDA Approves Nivolumab With Cisplatin-Gemcitabine for Unresectable or Metastatic UC
Zachary Bessette
Advanced Urothelial Carcinoma
|
March 7, 2024
Approval came as a result of the CheckMate 901 study, a randomized trial that enrolled 608 patients with metastatic UC.
Read More
EV Maintains HRQOL in Patients With Previously Treated Advanced UC
Emily Menendez
Advanced Urothelial Carcinoma
|
March 6, 2024
Patients who received EV over chemotherapy maintained their HRQOL levels and experienced delayed HRQOL deterioration.
Read More
Long-term Follow-up of TROPHY-U-01 Shows High ORR in Patients With UC
Emily Menendez
Advanced Urothelial Carcinoma
|
February 28, 2024
Patients with mutations in the UGT1A1 gene can experience adverse events when treated with irinotecan-based therapies.
Read More
Subgroup Analyses and Progression After EV-302
Thomas Powles, MBBS, MRCP, MD
Advanced Urothelial Carcinoma
|
March 7, 2024
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
View More
UNITE Study: Sequencing Erdafitinib and EV for Patients With FGFR2/3-Altered Disease
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
February 12, 2024
The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered.
View More
UNITE Study: Impact of Squamous, Other Histologies on Outcomes With EV
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
February 12, 2024
The impact of squamous and other histologies on outcomes with EV are dissected.
View More
UNITE Study: Design, Patients Sampled, and Outcomes With EV After Switch Maintenance Avelumab
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
February 12, 2024
The design of UNITE, patients sampled, and outcomes with EV after switch maintenance avelumab are explored.
View More
Sacituzumab Govitecan Offers Higher Response Rates Than Pembrolizumab in Patients With mUC
Emily Menendez
Advanced Urothelial Carcinoma
|
February 12, 2024
With a high response rate and manageable toxicity, further research into the use of SG in patients with mUC is warranted.
Read More
Panel Weighs in on Future Directions for Urothelial Carcinoma Treatment
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
May 1, 2024
The panel concludes with their forward-thinking thoughts on the impending direction of urothelial carcinoma treatment.
View More
ASCO GU Urothelial Cancer Study Roundup: EV, Atezolizumab, Erdafitinib, and More
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
May 1, 2024
The panel considered the latest available data pertaining to EV, atezolizumab, erdafitinib, and other therapy options.
View More
Panel Discusses ASCO GU Data Released on Sacituzumab Govitecan: Real-World Findings, UNITE Trial
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
May 1, 2024
The panel highlighted new data released on SG, including real-world findings and relevant results from the UNITE trial.
View More
AMBASSADOR Study Findings and Adjuvant Treatment for Urothelial Carcinoma
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
May 1, 2024
The panel transitioned to the AMBASSADOR trial findings and other adjuvant treatment considerations for urothelial carcinoma.
View More
Panel Discusses Treatment Selection After Progression on EV/Pembrolizumab
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
May 1, 2024
The panel weighed in on treatment selection after patient progression on EV/pembrolizumab.
View More
Treatment Options for Patients Not Eligible for the EV/Pembrolizumab Regimen
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
May 1, 2024
The panel considered treatment options for patients with mUC who are not eligible for EV/pembrolizumab.
View More
Load More
Advertisement
Advertisement
Advertisement